ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO617

Dysregulation of Fatty Acid Binding Protein and Its Relationship With Inflammatory Biomarkers in Atrial Fibrillation and Renal Dysfunction

Session Information

Category: Hypertension and CVD

  • 1501 Hypertension and CVD: Epidemiology‚ Risk Factors‚ and Prevention

Authors

  • Bansal, Vinod K., Loyola University Health System, Maywood, Illinois, United States
  • Bontekoe, Emily, Loyola University Health System, Maywood, Illinois, United States
  • Jaradeh, Mark, Loyola University Health System, Maywood, Illinois, United States
  • Allen, Madeline T., Loyola University Health System, Maywood, Illinois, United States
  • Hoppensteadt, Debra, Loyola University Health System, Maywood, Illinois, United States
  • Siddiqui, Fakiha, Loyola University Health System, Maywood, Illinois, United States
  • Iqbal, Omer M., Loyola University Health System, Maywood, Illinois, United States
  • Fareed, Jawed, Loyola University Health System, Maywood, Illinois, United States
  • Syed, Mushabbar, Loyola University Health System, Maywood, Illinois, United States
Background

Atrial Fibrillation (AF) represents a complex multi-factorial syndrome and is associated with renal compromise. Thrombo-inflammation plays an important role in the pathogenesis of cardiorenal syndrome associated with AF. Fatty acid binding proteins (FABPs) regulate transport of fatty acids and other lipophilic mediators includingeicosanoids. While upregulation of FABPs have been reported in AF and their relationship with inflammatory biomarkers is not fully understood. Liver fatty acid binding protein (L-FABP) also known as FABP-1 is a 14kDa protein expressed in the liver and tubular kidney cells. Kidney damage and other pathologic conditions secondary to AF result in the marked upregulation of this protein. This study was aimed to investigate the association of FABP with inflammatory biomarkers in the AF patient population and renal compromise.

Methods

Citrated blood samples from 70 AF patients with confirmed clinical diagnosis of atrial fibrillation were enrolled in this study. For comparison purposes normal human plasma collected from 50 normal healthy male and female individuals were used. Plasma prepared from these patients and normal individuals were analyzed for FABP-1 and such inflammatory biomarkers as IL-6, TNFa and inflammasome, using commercially available ELISA methods. All results were compiled and correlation analysis between FABP-1 levels and biomarkers of inflammation were carried out using GraphPad prism software.

Results

The AF patients showed a marked increase in FABP levels (13.1 + 1.1ng/ml) with a broad range (2.1 + 37.2) in comparison to normal (5.1 + 0.2ng/ml SEM) with a range of (3.4 - 9.2 ng/ml). Marked increases in IL-6, TNFa and inflammation were also noted (2 - 4 fold). FABP-1 showed varying degrees of positive correlation with inflammatory biomarkers.

Conclusion

These studies suggest that baseline plasma levels of FABP-1 is markedly increased in AF patients with renal compromise. Other biomarkers of inflammation are also upregulated and demonstrate varying degrees of correlation suggesting inter-relationship between FABP-1 and inflammatory processes. These results also suggest that atrial fibrillation and secondary damage to the kidneys contribute to the marked increase in FABP-1 and AF patients.